Literature DB >> 16139874

Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update.

Andreas Greinacher1, Theodore E Warkentin.   

Abstract

Heparin-induced thrombocytopenia (HIT) is one of the most important life- and limb-threatening adverse drug events encountered by physicians. Serious sequelae associated with HIT can be avoided with early recognition and appropriate treatment. This review examines the recommendations published in 2004 by the American College of Chest Physicians on the recognition, treatment, and prevention of HIT together with more recent data, especially regarding treatment with direct thrombin inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139874     DOI: 10.1016/j.thromres.2005.07.012

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  20 in total

1.  Case studies in anticoagulation management.

Authors:  Wendy A Leong
Journal:  J Thromb Thrombolysis       Date:  2007-10-01       Impact factor: 2.300

2.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

3.  Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital.

Authors:  Duane Bates; Sarah Griffin; Barb Angel
Journal:  Can J Hosp Pharm       Date:  2009-07

Review 4.  A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Authors:  Maximilian H M Hatz; Reiner Leidl; Nichola A Yates; Björn Stollenwerk
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

Review 5.  Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis.

Authors:  Zhengwu Sun; Xiaoyan Lan; Shen Li; Hongling Zhao; Zeyao Tang; Yalin Xi
Journal:  Int J Hematol       Date:  2017-06-09       Impact factor: 2.490

6.  Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.

Authors:  John R Bartholomew; Carolynn E Pietrangeli; Marcie J Hursting
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

7.  Platelet recruitment to venous stent thrombi.

Authors:  Robert D McBane; Krzysztof Karnicki; Waldemar E Wysokinski
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

8.  Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.

Authors:  Tamam Bakchoul; Andreas Greinacher
Journal:  Ther Adv Hematol       Date:  2012-08

9.  Effectiveness of a clinical decision support system to identify heparin induced thrombocytopenia.

Authors:  Jeffrey M Riggio; Mandelin K Cooper; Benjamin E Leiby; Jeanine M Walenga; Geno J Merli; Jonathan E Gottlieb
Journal:  J Thromb Thrombolysis       Date:  2008-10-07       Impact factor: 2.300

10.  Repeated early hemofiltration filters clotting and heparin-induced thrombocytopenia in ICU.

Authors:  Sébastien Perbet; Thomas Godet; Aurélien Lebreton; Anne-Françoise Sapin; Jean-Michel Constantin
Journal:  J Clin Monit Comput       Date:  2014-06-11       Impact factor: 2.502

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.